Protalix Biotherapeutics (PLX)
NYSE MKT:PLX
Holding PLX?
Track your performance easily

Protalix (PLX) Income Statement

741 Followers

Protalix Income Statement

Last quarter (Q2 2024), Protalix's total revenue was $13.47M, a decrease of -61.59% from the same quarter last year. In Q2, Protalix's net income was $-2.20M. See Protalix’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 38.05M$ 65.49M$ 47.64M$ 38.35M$ 62.90M$ 54.69M
Cost of Revenue
$ 25.81M$ 22.98M$ 40.00K$ -16.35M$ 10.87M$ 10.89M
Gross Profit
$ 12.25M$ 42.51M$ 47.64M$ 22.00M$ 52.02M$ 43.80M
Operating Expense
$ 46.93M$ 32.05M$ 41.06M$ 42.46M$ 49.31M$ 54.52M
Operating Income
$ -14.79M$ 10.46M$ -13.01M$ -20.46M$ 2.71M$ -10.72M
Net Non Operating Interest Income Expense
-$ 1.89M--$ -9.23M$ -7.56M
Other Income Expense
$ 365.00K$ 1.89M$ 1.38M$ 7.12M--
Pretax Income
$ -15.15M$ 8.57M$ -14.40M$ -27.58M$ -6.52M$ -18.28M
Tax Provision
$ -456.00K$ 254.00K$ 530.00K---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -14.69M$ 8.31M$ -14.93M$ -27.58M$ -6.52M$ -18.28M
Basic EPS
$ -0.20$ 0.12$ -0.31$ -0.62$ -0.22$ -1.23
Diluted EPS
$ -0.19$ 0.09$ -0.31$ -0.62$ -0.22$ -1.23
Basic Average Shares
$ 291.76M$ 67.51M$ 48.47M$ 44.14M$ 29.15M$ 14.84M
Diluted Average Shares
$ 335.36M$ 82.42M$ 48.47M$ 44.14M$ 29.15M$ 14.84M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 50.55M$ 55.03M$ 60.69M$ 58.81M$ 60.19M$ 65.41M
Net Income From Continuing And Discontinued Operation
$ -14.69M$ 8.31M$ -14.93M$ -27.58M$ -6.52M$ -18.28M
Normalized Income
$ -10.51M$ 6.77M$ -11.37M-$ -6.52M$ -18.28M
Interest Expense
----$ 9.67M$ 7.97M
EBIT
$ -14.38M$ 11.75M$ -14.40M$ -27.58M$ 3.15M$ -10.31M
EBITDA
$ -13.06M$ 12.94M$ -13.00M$ -23.81M$ 4.45M$ -8.69M
Currency in USD

Protalix Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis